Completed PHASE1 INTERVENTIONAL 5-arm NCT04169386

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

A First-in-Human,Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation,Phase 1 Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of AK102 in Healthy Subjects

Sponsor: AD Pharmaceuticals Co., Ltd.

Conditions Hypercholesterolaemia

Interventions AK102 Placebo

Updated 7 times since 2019 Last updated: Feb 27, 2025 Started: May 23, 2018 Primary completion: Nov 22, 2018 Completion: Nov 22, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hypercholesterolaemia, this trial is completed. The trial is conducted by AD Pharmaceuticals Co., Ltd. and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Mar 2025 — Sep 2025 [monthly]

Completed PHASE1
Sep 2024 — Mar 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jan 2021 — Oct 2021 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1

First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AD Pharmaceuticals Co., Ltd.
Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China